Bristol John W & Co. Inc. NY Has $65.15 Million Position in Becton Dickinson and Co (BDX)

Bristol John W & Co. Inc. NY lessened its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 4.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 304,350 shares of the medical instruments supplier’s stock after selling 13,914 shares during the period. Bristol John W & Co. Inc. NY’s holdings in Becton Dickinson and were worth $65,149,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Family Firm Inc. raised its holdings in Becton Dickinson and by 0.5% during the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after acquiring an additional 6 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its holdings in Becton Dickinson and by 0.4% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after acquiring an additional 6 shares in the last quarter. NBT Bank N A NY raised its holdings in Becton Dickinson and by 0.3% during the second quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock worth $654,000 after acquiring an additional 10 shares in the last quarter. Good Life Advisors LLC raised its holdings in Becton Dickinson and by 0.6% during the second quarter. Good Life Advisors LLC now owns 2,494 shares of the medical instruments supplier’s stock worth $491,000 after acquiring an additional 14 shares in the last quarter. Finally, Pathstone Family Office LLC raised its holdings in Becton Dickinson and by 0.4% during the second quarter. Pathstone Family Office LLC now owns 3,974 shares of the medical instruments supplier’s stock worth $2,530,000 after acquiring an additional 15 shares in the last quarter. Institutional investors and hedge funds own 75.53% of the company’s stock.

Several analysts recently issued reports on BDX shares. Argus upped their target price on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a report on Thursday, December 14th. They noted that the move was a valuation call. Wells Fargo & Co reiterated a “positive” rating and set a $235.00 target price (up previously from $225.00) on shares of Becton Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. KeyCorp started coverage on Becton Dickinson and in a report on Friday, January 5th. They set an “overweight” rating and a $260.00 target price on the stock. Morgan Stanley upped their target price on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $230.00 target price (up previously from $210.00) on shares of Becton Dickinson and in a report on Friday, November 3rd. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $230.20.

Becton Dickinson and Co (BDX) opened at $224.56 on Thursday. The firm has a market capitalization of $51,520.00, a P/E ratio of 48.29, a price-to-earnings-growth ratio of 1.70 and a beta of 1.07. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton Dickinson and Co has a 12-month low of $168.86 and a 12-month high of $229.68.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business’s revenue was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.12 earnings per share. equities analysts forecast that Becton Dickinson and Co will post 10.89 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 8th were given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend was Thursday, December 7th. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s payout ratio is 64.52%.

ILLEGAL ACTIVITY NOTICE: “Bristol John W & Co. Inc. NY Has $65.15 Million Position in Becton Dickinson and Co (BDX)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/01/11/bristol-john-w-co-inc-ny-has-65-15-million-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit